secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zymeworks Inc. (ZYME)
CIK:        0001937653
Form:       8-K
Filed at:   2023-09-21T23:59:59+00:00
Accession:  0001193125-23-239601
Event type: other_material
Sentiment:  negative
Materiality: 0.70
Item codes: 1.02, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zymeworks terminates ZW49 collaboration with BeiGene; ZW25 royalties reduced 0.5% until low double-digit million cap
--------------------------------------------------------------------------------

- Termination of ZW49 license with BeiGene ends potential $195M milestones and high single-digit to 20% royalties in Asia, Australia, NZ.
- Rights to zanidatamab zovodotin (ZW49) revert to Zymeworks.
- Third Amendment to ZW25 deal reduces royalties by 0.5% until cumulative cap (low double-digit millions) reached.
- No other changes to ZW25 agreement.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1937653/000119312523239601/0001193125-23-239601-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1937653/000119312523239601/d549533d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-23-239601

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer